Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
- Morgan Stanley increased its price target for SLM Corporation on September 2, 2026.
- An offering was filed with the SEC on July 22, 2025, involving Simmons Bank, with joint book-running management from Stephens Inc., Keefe, Bruyette & Woods, and Morgan Stanley, and co-management from Robert W. Baird & Co.
-
Cipla
Indian multi-national pharmaceutical and biotechnology company
Nothing else this week.
Related events
- Morgan Stanley reaffirmed an underweight rating and Citigroup restated a sell rating on Handelsbanken, reported by MarketBeat.
- Morgan Stanley upgraded Cboe Global Markets to an overweight rating on October 9, 2026.
- Morgan Stanley and Royal Bank of Canada initiated coverage of Csquare stock on August 10, 2026, setting ratings of overweight and outperform, respectively.
- Morgan Stanley reaffirmed an overweight rating on STMicroelectronics, and Eastern Bank raised its position in the shares.
- Citigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.